Loading…
← CockpitCompetitor Analysis › FAE.MC Faes Farma, S.A.Open in the cockpit ↗

Faes Farma, S.A.FAE.MCCompetitor analysis, valuation and peers

Spain · EUR·Health Care›Pharmaceuticals: Major

Spanish pharmaceutical company best known for the antihistamine bilastine, also making generics and animal-health products.

≈ A smaller, diversified generics/specialty pharmaMomentum strong 77
Mkt cap
$1.71B
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$824,302
20-day average traded
Fwd P/E
17.4×
forward earnings
ROIC−WACC
+1.4 pp
WACC 5.7%
Hurdle
-6 pp
Req g minus delivered
Next earnings
100 days
26 Feb 2027
Close · EUR€4.99
1D-0.5%
1W-0.3%
1M+2.9%
3M+9.2%
6M+6.0%
YTD-3.4%
1Y+8.7%
ATR %2.0%
52w lowhigh8.4% off high

What Faes Farma does

Spanish pharmaceutical company best known for the antihistamine bilastine, also making generics and animal-health products.

Licenses bilastine to pharmaceutical partners in many countries, who sell it under their own brands, while Faes earns by supplying the active ingredient and from licence payments. A separate business sells prescription and generic medicines in Spain through pharmacies and hospitals.

In one line: A smaller, diversified generics/specialty pharma.

Products and services

  • Bilastine (antihistamine)
  • Generic drugs
  • Animal health products
  • Nutraceuticals

Customers

  • Pharmacies
  • Hospitals
  • International licensing partners

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Branded + generic drug manufacturing

What could go right

  • International bilastine licensing royalties
  • Generics volume growth

What could go wrong

  • Generic drug price erosion
  • Bilastine patent expiry risk

Moat: narrow (IP / patents, distribution). Bilastine licensing income is a durable niche, but broader portfolio faces generic competition.

Headquarters: Bilbao, Spain · Founded: 1933

Named competitors

  • Almirall ALM.MC
  • Esteve (private) private or unlisted
  • Cinfa (private) private or unlisted
  • Zambon (private) private or unlisted

Faes Farma at a glance

Size Faes Farma (FAE.MC) is a Spain Health Care company (Pharmaceuticals: Major) with a market value of $1.71B, the 57th largest of 93 Spain companies the cockpit tracks. Shares closed at €4.99 on 18 Nov 2026.

Performance Over six months the shares gained 6.0%, against +1.7% for the median peer and +5.3% for the Spain market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 31.9% over the last twelve months (peer median +6.8%); the operating margin is 14.1% (peer median 8.6%).

Valuation It trades at 17.4× forward earnings against a peer median of 21.0× (6th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -6 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.4 points above its cost of capital (5.7% WACC).

Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026FAE.MC 105Peer median 103
Six months, rebased to 100: Faes Farma against the median of its 20 peers (local-currency closes).

Faes Farma financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€697M€610M€494M€451M€439M
Revenue growth—+24%+9%+3%—
Gross profit€259M€228M€201M€181M€172M
EBITDA€136M€102M€113M€101M€98.6M
Net income€84.2M€79.6M€111M€91.9M€89.5M
Free cash flow€61.6M€62.4M€81.7M€5.21M€31.8M
Capital expenditure€25.6M€23.6M€39.6M€102M€80.9M
Total debtn/a€410M€7.79M€8.23M€7.61M

Quarterly statements and history in the cockpit →

Faes Farma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%+20%MAZE300723CAPLIPOINT688166600993INDGNNATCOPHARM3003571681AGIO9989600664ETON3933ASTRAZEN301015FAE.MC6-month return →1-month return →
Up and to the right = strong over both horizons. Faes Farma is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×300723CAPLIPOINT688166600993INDGNNATCOPHARM30035716819989ETON3933301015ZYMEFAE.MCRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Faes Farma is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%300723CAPLIPOINT688166600993ETONFAE.MCGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Faes Farma is the large dot.

Faes Farma competitors and peer comparison

Head to head with its named competitors (FAE.MC vs ALM.MC)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Faes Farma FAE.MC$1.71B+6%+32%14%17.4×3.7%
Almirall ALM.MC$2.46B-13%+24%8%27.1×6.1%

How Faes Farma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Faes Farma against its 20 peers (data as of 18 Nov 2026)
MeasureFAE.MCPeer medianRank in peer set
1-month return+2.9%-1.4%7th highest of 21
6-month return+6.0%+1.7%6th highest of 20
Distance from 52-week high-8.4%-35.8%2nd highest of 21
Revenue growth (TTM)+31.9%+6.8%5th highest of 20
Operating margin14.1%8.6%8th highest of 20
Forward P/E17.4×21.0×6th cheapest of 16
Growth the price implies (Req g, 7 yrs)3.7%18.4%6th least demanding of 16
Growth delivered (Del g)+9.9%+9.2%8th highest of 16
Hurdle (Req g minus delivered)-6.2 pp+2.0 pp6th least demanding of 16
ROIC minus cost of capital+1.4 pp-2.7 pp9th highest of 21
EV / EBITDA13.4×21.5×3rd cheapest of 9
Net debt / EBITDA1.9×-1.4×2nd most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%17.0×-3.5%+6.8%
Indegene INDGN.NSIndia$1.69B+28%+36%12%29.5×31.4%+29.4%
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%26.3×18.4%+10.8%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%9.2×-14.9%+13.5%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Shenzhen Hepalink Pharmaceutical 9989.HKHong Kong$1.78B-13%-1%8%8.7×-0.4%-0.2%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%n/a33.0%+0.9%
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%n/a42.4%+23.0%
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a

Questions

Who are Faes Farma's main competitors?
Named competitors: Almirall (ALM.MC), Esteve (private) (private or unlisted), Cinfa (private) (private or unlisted), Zambon (private) (private or unlisted). The cockpit's measured peer set (industry) also includes Maze Therapeutics (MAZE), ApicHope Pharmaceutical (300723.SZ), Caplin Point Laboratories (CAPLIPOINT.NS), BrightGene Bio-Medical Technology (688166.SS), Mayinglong Pharmaceutical (600993.SS), Indegene (INDGN.NS).
Is Faes Farma expensive compared with its peers?
On forward p/e it trades at 17.4× against a peer median of 21.0×, 6th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -6 pp: the price already allows for a slowdown.
How has Faes Farma stock performed?
Over six months to 18 Nov 2026 the shares returned +6.0% against +1.7% for the median peer; over one year +8.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.